Biotech race and a rare-earth standoff: is the US-China truce cracking in 2026?

On June 22, 2026, two parallel storylines underscored how the US-China competition is shifting from rhetoric to measurable industrial leverage. A SCMP-cited survey by the Cure Innovation Index found that China now runs more clinical drug trials than the US, yet US leaders in industry and academia still rate China lower on biomedical science quality and commercial reach. In parallel, SCMP reported that Beijing has imposed new restrictions on US rare-earth companies, framed as retaliation after the Pentagon designated leading Chinese firms. The rare-earth measures target at least 10 US entities, including MP Materials, and analysts warned the move is testing the durability of a fragile US-China truce. Strategically, the biotech findings suggest a two-speed innovation contest: China is accelerating trial volume and execution capacity, while the US retains perceived advantages in quality signals, IP-to-market translation, and global commercialization networks. That asymmetry matters geopolitically because it can translate into future bargaining power over drug pipelines, regulatory standards, and cross-border supply of advanced therapies. The rare-earth episode is a more direct national-security lever, since export controls can quickly reshape downstream manufacturing options for magnets, EV components, defense systems, and clean-energy supply chains. In this clash, the Pentagon’s designations appear to have triggered Beijing’s retaliatory export controls, creating a tit-for-tat dynamic where both sides can claim industrial “security” while raising costs for firms caught in the middle. Market and economic implications are likely to concentrate in two sectors: life sciences/biotech R&D and strategic materials. If China’s trial throughput continues to outpace the US, investors may re-rate parts of the clinical-stage ecosystem, trial logistics, and contract research organizations, while US-focused platforms may emphasize differentiation in quality, regulatory credibility, and commercialization. On the rare-earth front, the immediate risk is higher compliance and supply uncertainty for companies exposed to dysprosium, neodymium, and related magnet supply chains, with potential knock-on effects for defense procurement readiness and EV/renewables component costs. While the articles do not provide price figures, the direction of risk is clearly upward for strategic-material volatility and downward for certainty in cross-border sourcing, which can lift hedging, inventory, and insurance premia. What to watch next is whether the rare-earth restrictions broaden beyond the initially named entities and whether Washington escalates with additional designations or enforcement actions. For biotech, the key indicator is whether US officials’ new steps to keep early research at home translate into measurable changes in trial location patterns, funding flows, and regulatory approvals over the next 1–2 quarters. In the near term, firms should monitor licensing outcomes, export-control guidance, and any signals of back-channel deconfliction that would stabilize the “truce” narrative. Trigger points include further Pentagon designations, additional Chinese export-control tightening, or visible shifts in clinical trial site selection that could affect timelines and cost curves for drug developers.

Geopolitical Implications

• 01

  Strategic-material leverage is being used as a national-security tool, raising the risk of sustained industrial friction.

• 02

  Trial capacity in biotech can become long-run influence through standards-setting and pipeline control.

• 03

  The US-China truce framing is fragile: designations and enforcement can trigger rapid reciprocal measures.

• 04

  Secondary jurisdictions like Australia may face spillover compliance and industrial-policy pressure.

Key Signals

• —Expansion of China’s rare-earth export-control targets beyond the initial list
• —Additional Pentagon designations or enforcement actions tied to strategic materials
• —Evidence that US localization steps change where early research and trials are conducted
• —Licensing outcomes and export-control guidance affecting affected firms